Showing results (371-380 of 396) with videos related to
Sort By:
Pageof 40
BMC Medicine|March 16, 2018
Impact of atopy on risk of glioma: a Mendelian randomisation studyLinden Disney-Hogg, Alex J Cornish, Amit Sud, et al.Nature Cancer|August 19, 2025
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cyclingWies R Vallentgoed, Youri Hoogstrate, Karin A van Garderen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 OligodendrogliomaSalah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret, et al.Nature Communications|February 12, 2026
STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathwaysMark W Youngblood, Shashwat Tripathi, Hinda Najem, et al.Cancer Cell|January 12, 2024
Integrated proteogenomic characterization of glioblastoma evolutionKyung-Hee Kim, Simona Migliozzi, Harim Koo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.Human Molecular Genetics|May 3, 2011
Chromosome 7p11.2 (EGFR) variation influences glioma riskMarc Sanson, Fay J Hosking, Sanjay Shete, et al.Trends in Cancer|November 18, 2022
Challenges in glioblastoma research: focus on the tumor microenvironmentAndreas Bikfalvi, Cristine Alves da Costa, Tony Avril, et al.Nature Medicine|December 12, 2018
The molecular landscape of glioma in patients with Neurofibromatosis 1Fulvio D'Angelo, Michele Ceccarelli, Tala, et al.Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.Pageof 40